-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Fosun Pharmaceutical's announcement, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., a holding subsidiary of the company, has received clinical trial approval from the State Drug Administration to approve [18F] F-SR031 injection for positron emission tomography imaging of fibroblast-activating protein-positive lesions in patients with solid tumors, and plans to conduct phase I clinical research in China after conditions are met. SRT-003-1 is a radiologic in vivo diagnostic drug targeting FAP. As of October 2026, the Group has invested a total of about 25 million yuan in research and development of this drug. Currently, no radiological diagnostic drug targeting FAP has been approved for marketing in China, and there is uncertainty about the subsequent development and marketing of this drug.
Share
Listen to the news
According to Fosun Pharmaceutical's announcement, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., a holding subsidiary of the company, has received clinical trial approval from the State Drug Administration to approve [18F] F-SR031 injection for positron emission tomography imaging of fibroblast-activating protein-positive lesions in patients with solid tumors, and plans to conduct phase I clinical research in China after conditions are met. SRT-003-1 is a radiologic in vivo diagnostic drug targeting FAP. As of October 2026, the Group has invested a total of about 25 million yuan in research and development of this drug. Currently, no radiological diagnostic drug targeting FAP has been approved for marketing in China, and there is uncertainty about the subsequent development and marketing of this drug.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending